blog

Introduction: Dasatinib is a potent tyrosine kinase inhibitor that has emerged as a significant player in the field of targeted cancer therapy. Approved by the U.S. Food and Drug Administration (FDA) in 2006, Dasatinib has shown remarkable efficacy in treating certain types of cancer, particularly chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia…